{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-148151","form_type":"8-K","ticker":"VOR","cik":"0001817229","company_name":"Vor Biopharma Inc.","filed_at":"2024-05-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.319696+00:00","generated_at":"2026-06-01T08:11:39.164924+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Vor Biopharma shareholders approve equity plan amendment to 5% annual share increase, elect directors","bullets":["Shareholders approved amended 2021 Equity Incentive Plan raising automatic annual share increase from 4% to 5% through 2034.","Robert Ang and Sven (Bill) Ante Lundberg were elected as Class III directors until the 2027 annual meeting.","Ernst & Young ratified as independent auditor for fiscal year 2024.","Plan amendment received 36.8M votes for, 20.9M against; 4.4M broker non-votes."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-148151","json":"https://secwatch.observer/filing/0001193125-24-148151.json","markdown":"https://secwatch.observer/filing/0001193125-24-148151.md","text":"https://secwatch.observer/filing/0001193125-24-148151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524148151/0001193125-24-148151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1817229/000119312524148151/d829841d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T08:11:39.164924+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}